Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 453

1.

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Johnson JA, Majumdar SR, Simpson SH, Toth EL.

Diabetes Care. 2002 Dec;25(12):2244-8.

PMID:
12453968
2.

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.

PMID:
16443869
3.

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA.

Diabetes Care. 2005 Oct;28(10):2345-51.

PMID:
16186261
4.

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.

Eurich DT, Simpson SH, Majumdar SR, Johnson JA.

Pharmacotherapy. 2005 Jun;25(6):810-6.

PMID:
15927899
5.

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.

Johnson JA, Simpson SH, Toth EL, Majumdar SR.

Diabet Med. 2005 Apr;22(4):497-502.

PMID:
15787679
6.

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

Bowker SL, Yasui Y, Veugelers P, Johnson JA.

Diabetologia. 2010 Aug;53(8):1631-7. doi: 10.1007/s00125-010-1750-8. Epub 2010 Apr 21.

PMID:
20407744
7.

Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.

Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE, Pogach LM.

Diabetes Care. 2007 Jul;30(7):1689-93. Epub 2007 Apr 17.

PMID:
17440170
8.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
9.
10.
11.
12.

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.

Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA.

CMAJ. 2006 Jan 17;174(2):169-74.

13.
14.

Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.

Gulliford M, Latinovic R.

Diabetes Metab Res Rev. 2004 May-Jun;20(3):239-45.

PMID:
15133756
16.

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.

Evans JM, Ogston SA, Emslie-Smith A, Morris AD.

Diabetologia. 2006 May;49(5):930-6. Epub 2006 Mar 9.

PMID:
16525843
17.

Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.

Becker ML, Aarnoudse AJ, Newton-Cheh C, Hofman A, Witteman JC, Uitterlinden AG, Visser LE, Stricker BH.

Pharmacogenet Genomics. 2008 Jul;18(7):591-7. doi: 10.1097/FPC.0b013e328300e8c5.

PMID:
18551039
18.

Coronary heart disease outcomes in patients receiving antidiabetic agents.

McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.

PMID:
17551989
19.
20.

Anti-diabetic drug use and the risk of motor vehicle crash in the elderly.

Hemmelgarn B, Lévesque LE, Suissa S.

Can J Clin Pharmacol. 2006 Winter;13(1):e112-20. Epub 2006 Mar 31.

PMID:
16585812

Supplemental Content

Support Center